Wells Fargo
RLMD icon

Wells Fargo’s Relmada Therapeutics RLMD Stock Holding History

Wells Fargo’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,800
Closed -$437K – 7684
2022
Q3 		$437K Sell
11,800
-8,200
-41% -$227K ﹤0.01% 3768
2022
Q2 		$380K Buy
+20,000
New +$436K ﹤0.01% 3901

Other funds holding RLMD

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Wells Fargo's RLMD Position: Q1 2025 in Review

Wells Fargo sold out of Relmada Therapeutics (RLMD) in Q1 2025, closing a stake of 200 shares — an estimated $104 sold.

Wells Fargo first reported a position in RLMD in Q4 2019 and held it in 21 quarters. The position peaked at $1.74M in Q2 2020. 44 funds tracked by Wall St. Rank hold RLMD as of Q1 2025.

  • Wells Fargo reported no remaining Relmada Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wells Fargo sold 200 Relmada Therapeutics shares in Q1 2025, an estimated $104.
  • Wells Fargo first reported a position in Relmada Therapeutics in Q4 2019 and held it in 21 quarters.
  • Wells Fargo's Relmada Therapeutics position peaked at $1.74M in Q2 2020.
  • 44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2025.

Based on Wells Fargo's 13F filing for Q1 2025, filed 13 May 2025.